Cannabidiol (CBD) is one of the naturally occurring cannabinoids, found in cannabis plants. It is a 21-carbon terpenophenolic compound which is formed following decarboxylation from a cannabidiolic acid precursor.
As stated in WHO Critical Review Report (2018), “CBD does not appear to have any psychotropic (“high”) effects such as those caused by ∆9-THC in marijuana. CBD is generally well tolerated with a good safety profile.”
As of 2018, preliminary clinical research on cannabidiol included studies of anxiety, cognition, movement disorders, and pain.
ABOUT Endocannabinoid System
The endocannabinoid system (ECS) is a biological system composed of endocannabinoids, being in human body as well.
The endocannabinoid system is our body’s natural balancing mechanism in regulating a variety of physiological and cognitive processes including appetite, pain-sensation, mood, sleep, our immune system, fertility and memory.
Sometimes due to the stressors of modern life, this internal balance can become compromised.
The ECS is also involved in mediating some of the physiological and cognitive effects of voluntary physical exercise in humans and animals, such as contributing to exercise-induced euphoria as well as modulating locomotor activity and motivational salience for rewards.
Two primary endocannabinoid receptors have been identified: CB1, first cloned in 1990, and CB2, cloned in 1993.
One main endocannabinoid is 2-arachidonoylglycerol (2-AG) which is active at both cannabinoid receptors, along with its own mimetic phytocannabinoid, CBD. 2-AG and CBD are involved in the regulation of appetite, immune system functions and pain management.
The cannabidiol (CBD) is the main cannabinoid within the industrial hemp (Cannabis sativa L.) which is the origin of the natural paste incorporated into matrix of CeBeDot sublingual thin film.
Hemp paste, used in CeBeDot, is prepared with care from defined European plant sources.
Natural paste contains therefore CBD with all the richness of other natural components.
A comprehensive set of Quality Parameters is regularly controlled. High quality is assured constantly.
THC is well below 0,05% and therefore you can not expect any psychotropic effect.
ABOUT SUBLINGUAL APPLICATION
Sublingual administration-under tongue administration-has certain advantages over classical oral administration, where the substance must pass a gastrointestinal tract. It is often faster and a chemical enters the bloodstream directly through tissues under the tongue, whereas orally administered drugs must survive passage through the hostile environment of the gastrointestinal tract, which risks degrading them. Furthermore, after absorption from the gastrointestinal tract, such drugs must pass to the liver, where they may be extensively altered; this is known as the first pass effect of drug metabolism.
As stated in WHO Critical Review Report (2018):
“In clinical trials and research studies, CBD is generally administered orally as either a capsule, or dissolved in an oil solution (e.g., olive or sesame oil). It can also be administered through sublingual or intranasal routes.
Bioavailability from oral delivery was estimated to be 6% due to significant first-pass metabolism.
CBD is extensively metabolised in the liver. The primary route is hydroxylation to 7-OH-CBD which is then metabolised further resulting in a number of metabolites that are excreted in faeces and urine.”
ABOUT SUBLINGUAL THIN FILMS
Thin films have been identified as a line-extension approach to conventional dosage forms, ie tablets and capsules. The thin films are considered to be safe, reliable, precise and pain-free application, ideal for patients who have difficulty swallowing.
Furthermore it is widely recognised that there is a possibility of avoidance of the first-pass effect and improved bioavailability as an active substance can be delivered directly to the systemic circulation (see above: About sublingual application).
Polymers are used as film formers to hold active substances and excipients in place.
Some drugs are already designed for sublingual administration, including cardiovascular drugs, steroids, barbiturates, benzodiazepines, opioid analgesics, enzymes and, increasingly, vitamins and minerals.
Conventional sublingual thin films are similar in size, shape and thickness to a postage stamp.
About Cebedot thin films
CeBeDot’s superbly defined sublingual film formulation enables fast and direct transfer of CBD and other natural components to bloodstream. Dissolution time is well defined within narrow limits of few minutes (tipically 1-4 min) and could vary on a personal level.
A very precise dosing technology is utilised during the production and consequently a dose of film is perfectly accurate and repeatable.
As it has a perfect stability at room temperature (up to 25°C, protected from light), CeBeDot thin films will maintain a starting high quality without keeping them in fridge.
CeBeDot – utilises the proprietary technology.
And CeBeDot is even more – it is about your convenience, well-being and life style.
You can take thin films anywhere and any time as they are small, compact, portable, discreet and can be taken without any preparation. You can keep them in your pocket, purse, drawer, being at home or outdoor, at work or traveling.
You can select your favorite flavor and preferred strength.
Explore a positive impact on your well-being and lifestyle.
You might even decide to contact us for a special experience of custom made thin films with different shapes, colors and tastes where the superb characteristic of the film are not jeopardized at all.
to read more:
Bala, R., Pawar, P., Khanna, S., Arora, S., (2013). “Orally dissolving strips: A new approach to oral drug delivery system”. Int J Pharm Investig. 2013 Apr-Jun; 3(2): 67–76.
Boggs, D., Nguyen, J.D., Morgenson, D., Taffe, M.A., Ranganathan, M.; (2017). “Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol”. Neuropsychopharmacology. 43 (1): 142–154.
Cannabidiol (CBD), Critical Review Report, (2018). Expert Committee on Drug Dependence Fortieth Meeting, WHO, Geneva, 4-7 June 2018; Collected from https://www.who.int/medicines/access/controlled-substances/CannabidiolCriticalReview.pdf.
Grotenhermen, F., (2012). “The Therapeutic Potential of Cannabis and Cannabinoids”. Dtsch Arztebl Int. 109 (PMC3442177): 495–501.